Background: Antimicrobial resistance is a major health problem worldwide. We evaluated the antimicrobial resistance trends of 16 major bacterial pathogens at a tertiary medical center in northern Taiwan. Methods: We conducted a retrospective review of annual summary documents for antimicrobial susceptibility of clinically isolated gram-positive and gram-negative bacteria from 1985 to 2005. The numbers of isolates and susceptibilities were calculated for three 7-year periods: first period, 1985e1991; second period, 1992e1998; and the third period, 1999e2005. Results: During the 21-year period, 219,715 bacterial pathogens were identified. A significant increase in incidence over time was found for methicillin-resistant Staphylococcus aureus, methicillin-resistant S epidermidis, penicillin-nonsusceptible Streptococcus pneumoniae, erythromycin-resistant S pneumoniae, vancomycin-resistant enterococci, cefotaxime/ceftriaxoneresistant Escherichia coli and Klebsiella pneumoniae, and imipenem-resistant Acinetobacter baumannii. Additionally, a significant increase in ciprofloxacin resistance rates over time from 1996 to 2005 was noted for E coli, Enterobacter cloacae, and A baumannii (through 1997 to 2005). However, a significant decrease in erythromycin resistance rate with time from 1999 to 2005 was found for Groups A and B streptococci, non-A, B, D streptococci, and S pneumoniae. Conclusion: Resistance to antimicrobial agents increased rapidly in the past two decades in Taiwan and has become very common in major bacterial pathogens. Continuous enforcement of policies to limit use of antimicrobial agents and active surveillance of antimicrobial resistance through a nationwide system are both warranted.
Introduction
Antimicrobial resistance is an increasing threat to patients in health care settings as well as in the community, and mortality and morbidity from infection are greater when caused by antimicrobial-resistant bacteria.
1e4 Taiwan has one of the highest levels of antimicrobial resistance in the world, and previous studies in Taiwan clearly demonstrated the remarkably high prevalence of some critically resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-nonsusceptible Streptococcus pneumoniae (PNSSP), macrolide-resistant streptococci, third-generation cephalosporin-resistant Enterobacteriaceae, imipenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and ciprofloxacin-resistant Enterobacteriaceae. 5e13 Importantly, understanding the hospital antibiogram is mandatory in solving the problem of antimicrobial resistance in hospitals. 14 In the past, over-the-counter antibiotic use as well as the widespread use of antimicrobial agents in animal husbandry spurred the rapid emergence of resistant bacteria in Taiwan. 5, 15 Since 1995, medical payments have been regulated by the National Health Insurance System and a restrictive governmental policy to deny reimbursement through the National Health Insurance System for the costs of antibiotics used for the treatment of acute upper respiratory tract infections without evidence of bacterial involvement was implemented in 2001. 16 In addition, many other measures to control resistance problems were instituted in Taiwan, including more rigorous enforcement of prescription-filling practices in the pharmacy (starting in 1997), educational programs about appropriate antibiotic use for physicians and patients (starting in 1998), prohibition of several antimicrobial agents (such as avoparcin, kanamycin, and spiramycin) in animal husbandry by the Council of Agriculture in 2000, and antibiotic interventions were implemented in most hospitals in recent years. 5, 16 To understand the prevalence and trends of antimicrobial resistance among major bacterial pathogens in the past two decades in Taiwan, a retrospective review of the annual summary documents for antimicrobial susceptibility of clinically isolated gram-positive and gram-negative bacteria (GNB) from 1985 to 2005 in Tri-Service General Hospital (TSGH) were retrieved.
Methods
Setting TSGH, a tertiary care medical center located in Taipei city, northern Taiwan, had 1,200 beds in 1985 and 1,700 beds in 2005. The entire hospital moved to new facilities in 2000, with less crowding and larger interbed space, and a smaller proportion of intensive care unit beds to general ward beds. The Nosocomial Infection Control Committee of the hospital was established in 1984. Before 1999, no specific and wellestablished antibiotic control policies were implemented at the hospital. All attending physicians at the hospital prescribed nearly all antimicrobial agents without consultation with hospital infectious disease specialists.
Data collection
All clinical specimens for bacterial growth and isolation were sent to the central laboratory in the department of clinical pathology at TSGH. These specimens included those from hospitalized in-patients, patients in the emergency services, and patients in the outpatient clinics of all services. In this analysis, there were totally 16 major bacterial pathogens studied, including S aureus, coagulase-negative staphylococci (focus on S epidermidis), S pneumoniae, other streptococci (including Groups A and B streptococci, non-A, B, and D streptococci and viridans streptococci), Enterococcus sp (including E faecalis and E faecium), Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter sp (focus on E cloacae), Serratia marcescens, P aeruginosa, and Acinetobacter sp (focus on A baumannii). These isolates were nonduplicate samples, as several isolates of one species from each patient recovered within 7 days were considered one isolate. Isolates were identified by standard methods and were confirmed using Vitek or API products (bioMerieux Vitek Inc., Hazelwood, MO, USA). The numbers of isolates were calculated for three 7-year periods: first period, 1985e1991; second period, 1992e1998; and the third period, 1999e2005.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing of the 16 major bacterial pathogens was performed by the disk-diffusion method. Isolates were classified as susceptible or resistant (including intermediate category) by the annually renewed Clinical Laboratory Standards Institute (CLSI; formerly known as the NCCLS) guidelines. 17, 18 Screening for extended-spectrum b-lactamase (ESBL) phenotypes among K pneumoniae and E coli began in 2005. Isolates displaying positive double-disk synergy were considered ESBL producers. Double-disk confirmatory tests were performed using cefotaxime, cefotaxime-clavulanate, ceftazidime, and ceftazidimeclavulanate to confirm the ESBL phenotype. 17 The antimicrobial susceptibilities were summed for each of the 7-year periods indicated above.
The antimicrobial resistance data for S epidermidis isolates were not categorized by coagulase negativity and positivity until 2004; isolates of Streptococcus sp other than S pneumoniae were represented as "other streptococci" before 1997; isolates of Group A streptococci; viridans streptococci; Group B streptococci; and non-A, B, and D streptococci were separated from "other" streptococcal isolates since 1999. In addition, since 1997, isolates of E cloacae were separated from Enterobacter sp and isolates of A baumannii were similarly separated from Acinetobacter sp. E faecalis and E faecium isolates were separated from Enterococcus sp when they were isolated from expectedly sterile sites after 1999.
Trends in resistance
To determine the secular resistance trends of major bacterial pathogens at TSGH, the disk-diffusion susceptibility data of these organisms were retrieved from 1985 to 2005 annual summary documents. To calculate the resistance rates, isolates of each species with identical resistance profiles recovered from one patient within 7 days were counted as one isolate.
Statistical analysis
Pearson's correlation coefficient was used to determine the relationship between time series and resistance trends. Annual trends of resistance to each antimicrobial agent for each of the 16 bacteria studied were calculated using Durbin-Watson statistics. An r value greater than 0.72 (or less than À0.72) and a p value less than 0.05 were considered statistically significant.
Results
Resistance rates Table 1 shows the years when the selected antibiotics were approved at TSGH. During the 21-year period, 219,715 bacterial pathogens were identified. The sums of isolates by genus and species and antimicrobial susceptibilities of gram-positive bacteria and gram-negative bacteria (GNB) for each of the three 7-year periods are shown in Tables 2  and 3 , respectively. Among S aureus isolates, the resistances to methicillin, clindamycin, cephazoline, erythromycin, and gentamicin were high (!75%) and increased substantially after the first period (1985e1991). Vancomycin remained the most active agent for clinical S aureus isolates. For S epidermidis isolates, the high prevalence of antimicrobial resistance was as the same as that of S aureus. Furthermore, susceptibilities to penicillin, ampicillin, clindamycin, and erythromycin among S pneumoniae isolates remained low and decreased proportionally after the first period. During the third period (1999e2005), resistance to penicillin, clindamycin, and erythromycin were 75.6%, 67.3%, and 92.0%, respectively. All clinical S pneumoniae isolates were susceptible to vancomycin. In contrast to S pneumoniae, the antimicrobial susceptibilities of other streptococci did not decrease after the first period. Of the enterococci, 10%e17% was resistant to ampicillin and 63.9% were resistant to high-level gentamicin in the third period. The rate of vancomycin resistance was 22% during the third period. Additionally, E faecalis isolates were resistant to ampicillin (2.4%), vancomycin (5.2%), and high-level gentamicin (67.3%); E faecium isolates were much more resistant to ampicillin (83.7%), vancomycin (27.5%), and high-level gentamicin (79.1%).
Both E coli and K pneumoniae isolates were highly resistant to cefazolin and gentamicin (Table 3) . Increasing resistance to third-generation cephalosporins was observed among these isolates throughout the three periods. P mirabilis isolates were highly susceptible to third-generation cephalosporins, amikacin, imipenem, and aztreonam (>95%). In contrast, Enterobacter isolates (including E cloacae) were less susceptible to third-generation cephalosporins, amikacin, and aztreonam (46.4e89.5%), whereas susceptibility to imipenem remained high (>98%). Although S marcescens and P aeruginosa isolates remained susceptible to ceftazidime (>90% and >80%, respectively), resistance to ceftazidime was increasing among both pathogens. In the third period, the overall rate of resistance to imipenem was 4.8% for A baumannii and 16.8% in P aeruginosa. Thus, imipenem was the most active agent for the GNB isolates tested during the study period. Additionally, based on the CLSI guidelines for ESBL confirmation testing, 17 the percentage of ESBL-producing K pneumoniae (307/1,858, 16.5%) was greater than that for E coli (182/ 3,326, 5.4%) in 2005. streptococci; and in S pneumoniae isolates (r < À0.72 and p < 0.05). Figure 3 demonstrates the secular trends for cefotaxime/ ceftriaxone-resistant E coli and K pneumoniae, ceftazidimeresistant P aeruginosa isolates (since 1988), imipenemresistant P aeruginosa isolates (since 1990), and imipenemresistant A baumannii isolates (since 1997). Resistance to cefotaxime/ceftriaxone by E coli and K pneumoniae isolates and resistance to imipenem by A baumannii isolates increased significantly with time (r > 0.72 and p < 0.05). Resistance to imipenem by A baumannii emerged in 2002 and remained at 6.9e8.4% throughout the study periods. Resistance to ceftazidime (9e23%) and imipenem (11e24%) by P aeruginosa remained steady over the study periods.
Resistance trends
Ciprofloxacin resistance of the major GNB from 1996 to 2005 is shown in Fig. 4 . A baumannii and S marcescens isolates were more resistant to ciprofloxacin from 1996 to 2005 than were other GNB isolates. E coli (from 1996 to 2005), E cloacae (from 1996 to 2005), and A baumannii (from 1997 to 2005) resistance to ciprofloxacin increased significantly with time (r > 0.72 and p < 0.05).
Discussion
Our results demonstrate that resistance to antimicrobial agents increased rapidly during the past two decades in Taiwan. MRSA was first documented in Taiwan in the early 1980s. 19 Since then, the prevalence of MRSA infections markedly increased for both nosocomial-and communityacquired infections.
20e25 Several dominant clones are prevalent in hospitals and in the community.
20e25 A nationwide survey showed that MRSA isolates increased from 52% to 61% between 1998 and 2000. 6 MRSA isolates increased rapidly in our hospital from 33% in 1990, peaking at 87.4% in 2000, and decreasing significantly thereafter to 75.2% in 2004. The rate of MRSA in this report is higher than in previously reported studies in Taiwan and other  countries. 5e7, 11, 20, 26 Although MRSA isolates are still largely susceptible to vancomycin, the first S aureus isolate with intermediate resistance to vancomycin (minimum inhibitory concentration, 8 mg/mL) isolated from synovial fluid and a knee wound from a patient with septic arthritis in our hospital was reported in 2005. 27 Furthermore, the increase in MRSE in our report is worrisome because coagulasenegative staphylococci are the leading cause of blood stream infections, as revealed in the 1999 National Nosocomial Infections Surveillance study. 28 Taiwan has a relatively low prevalence of VRE (3e7% of isolates), 5e7,10,11 in contrast to the high prevalence of VRE in United States intensive care units, where the rate was about 28% from 2001 and 2004. 29 The high prevalence of VRE (22% in the third study period) in our analysis could be a During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter species were evaluated from 3,488; 2,857; 952; 1,379; 792; 5,219; and 1,378 isolates, respectively b During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter species were evaluated from 5,480; 4,595; 1,512; 2,643; 1,254; 7,836; and 2,486 isolates, respectively c During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter species were evaluated from 2,786; 2,321; 763; 975; 541; 3,864; and 982 isolates, respectively d SXT and NA were only tested for isolates obtained from urine samples. AM Z ampicillin; AN Z amikacin; ATM Z aztreonam; CAZ Z ceftazidime; CIP Z ciprofloxacin; CRO Z ceftriaxone; CTX Z cefotaxime; CZ Z cefazolin; GM Z gentamicin; IPM Z imipenem; NA Z nalidixic acid; PIP Z piperacillin; SXT Z trimethoprim/sulfamethoxazole.
because of the policy of routinely screening every patient admitted to the intensive care units in our hospital for VRE; thus, enterococci isolates included in this report are colonizing and infecting isolates. Additionally, a previous nationwide study in Taiwan showed that the rate of highlevel gentamicin resistance among E faecalis and E faecium isolates was 66% and 62%, respectively. 6 The higher rates of HLGRE (around 65e75%) in the present report could correlate with administration of aminoglycosides because they are the second most frequently used antimicrobial category in Taiwan hospitals. 14, 30 The prevalence of PNSSP increased rapidly from 0% in 1993 to very high levels of 73.3% in 2004 and 88.9% in 2005 in our hospital. Although our PNSSP rate was lower than that reported for Vietnam where the PNSSP prevalence was 92% among clinical isolates during the 2000e2001 period, 8 we report the highest prevalence of PNSSP in Taiwan. 5 16 ,31 also demonstrated a decline in erythromycin consumption and resistance rates of Group A streptococci, but a continued increase in erythromycin resistant S pneumoniae was found. The relatively small numbers of S pneumoniae isolates in our report could contribute to the differing results between two hospitals.
A previous study in Taiwan conducted by Jean et al. 32 stated that cefotaxime-resistant E coli (33.3%) and K pneumoniae isolates (58.4%) exhibited ESBL. In our hospital, among ceftriaxone-resistant E coli and K pneumoniae isolates tested in 2004, 27.5% and 58.2%, respectively, exhibited the ESBL phenotype. In the Asia-Pacific region, ESBL-producing isolates showed high levels of coresistance to aminoglycosides, tetracycline, trimethoprim-sulfamethoxazole, and ciprofloxacin. 33 Although all the ESBLproducing isolates were susceptible to imipenem at our hospital, indiscriminate use of imipenem could promote imipenem resistance.
32e35 Thus, establishment of alternative agents for use against ESBL producers is crucial at the individual hospital level because interhospital variation of these data occur. 34 Ciprofloxacin was launched in Taiwan in 1991, and a dramatic increase in the prescription of fluoroquinolones in Taiwan has occurred thereafter. 13 Sheng et al. 13 reported the rapid increase in ciprofloxacin-resistant E coli, Morganella morganii, S marcescens, P aeruginosa, and E cloacae in 1996e1997, following the widespread use ciprofloxacin in Taiwan. Additionally, we also report a significantly increasing trend in ciprofloxacin resistance over time for E coli (1996e2005), E cloacae (1996e2005), and A baumannii (1997e2005).
An effective strategy to limit the effects of increasing high antimicrobial resistance must be multifaceted and must include education of patients and physicians about appropriate antimicrobial use, use of effective infection control practices to prevent transmission from infected to uninfected patients, surveillance of antimicrobial resistance and antimicrobial use, improved use of immunization, and development of alternative therapies that would circumvent the need for antimicrobial therapy. 29, 30, 36 The government policy of restricting antibiotic use for acute respiratory tract infections without evidence of bacterial infection in Taiwan in 2001 resulted in a decrease in the use of penicillins, cephalosporins, and macrolides and also reduced macrolide-resistant Group A streptococcus. 16 In addition, the hospital moved to new facilities with a smaller proportion of intensive care units beds and wider interbed spaces, which could have contributed to the significant decrease in the rate of MRSA after 2000 and the relatively low prevalence of imipenem-resistant A baumannii in our hospital.
In conclusion, this 21-year study in a medical center in northern Taiwan demonstrated significant changes in antimicrobial resistance among major bacterial pathogens.
Dissemination and feedback of these data to clinicians and decision makers at our hospital and others is crucial to improve antibiotic prescribing and to implement effective infection control. 
